01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
In its first installment of opinions letters in 2020, the U.S. Department of Labor’s Wage and Hour ...
Read More >
On January 28, 2020, the Federal Trade Commission (FTC) announced an increase in the thresholds dete...
Read More >
In this episode of Trekking Through Compliance, we consider the episode The Cloud Miners which aired...
Read More >
Arbitration is a strongly favored federal policy and generally can be relied on to resolve even stat...
Read More >
The coronavirus pandemic is taxing government services and infrastructure in numerous ways, and many...
Read More >
Please contact a Jackson Lewis attorney if you have any questions about these developments. ©2019 Ja...
Read More >